ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis Licenses T Cell Technology

by Michael McCoy
October 20, 2014 | APPEARED IN VOLUME 92, ISSUE 42

Novartis will pay the English firm Oxford BioMedica $14 million up front and possibly $90 million more over the next three years for a nonexclusive license to OXB’s viral vector technology. OXB will manufacture gene-carrying vectors for Novartis. Novartis, in turn, will use OXB’s technology to insert the instructions for a chimeric antigen receptor into the white blood cells known as T cells. T cells, so enhanced to home in on cancer, are the basis of a Novartis immunotherapy called CTL019/CART-019 (C&EN, Oct. 6, page 12).

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment